| Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir ML Cottrell, T Hadzic, ADM Kashuba Clinical pharmacokinetics 52, 981-994, 2013 | 345 | 2013 |
| A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without … ML Cottrell, KH Yang, HMA Prince, C Sykes, N White, S Malone, ... The Journal of infectious diseases 214 (1), 55-64, 2016 | 307 | 2016 |
| Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery SR Benhabbour, M Kovarova, C Jones, DJ Copeland, R Shrivastava, ... Nature communications 10 (1), 4324, 2019 | 112 | 2019 |
| Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues ML Cottrell, KL Garrett, HMA Prince, C Sykes, A Schauer, CW Emerson, ... Journal of Antimicrobial Chemotherapy 72 (6), 1731-1740, 2017 | 68 | 2017 |
| Decreased tenofovir diphosphate concentrations in a transgender female cohort: implications for human immunodeficiency virus preexposure prophylaxis ML Cottrell, HMA Prince, AP Schauer, C Sykes, K Maffuid, A Poliseno, ... Clinical Infectious Diseases 69 (12), 2201-2204, 2019 | 58 | 2019 |
| Smartphone-based contingency management intervention to improve pre-exposure prophylaxis adherence: pilot trial JT Mitchell, S LeGrand, LB Hightow-Weidman, MS McKellar, ... JMIR mHealth and uHealth 6 (9), e10456, 2018 | 58 | 2018 |
| Pharmacokinetics of antiretrovirals in mucosal tissue ML Cottrell, N Srinivas, ADM Kashuba Expert opinion on drug metabolism & toxicology 11 (6), 893-905, 2015 | 53 | 2015 |
| Topical microbicides and HIV prevention in the female genital tract ML Cottrell, ADM Kashuba The Journal of Clinical Pharmacology 54 (6), 603-615, 2014 | 41 | 2014 |
| Safety and pharmacokinetics of a tenofovir alafenamide fumarate-emtricitabine based oral antiretroviral regimen for prevention of HIV acquisition in women: a randomized … AR Thurman, JL Schwartz, ML Cottrell, V Brache, BA Chen, L Cochón, ... EClinicalMedicine 36, 2021 | 36 | 2021 |
| Validation of an LC–MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots AP Schauer, C Sykes, ML Cottrell, H Prince, ADM Kashuba Journal of pharmaceutical and biomedical analysis 149, 40-45, 2018 | 34 | 2018 |
| A translational pharmacology approach to predicting HIV pre-exposure prophylaxis outcomes in men and women using tenofovir disoproxil fumarate+/-emtricitabine ML Cottrell, KH Yang, HMA Prince, C Sykes, N White, S Malone J Infect Dis 214 (1), 55-64, 2016 | 33 | 2016 |
| Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy J Blazkova, F Gao, MH Marichannegowda, JS Justement, V Shi, ... Nature Medicine 27 (11), 1893-1898, 2021 | 32 | 2021 |
| A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host AF Feder, C Kline, P Polacino, M Cottrell, ADM Kashuba, BF Keele, SL Hu, ... PLoS pathogens 13 (5), e1006358, 2017 | 30 | 2017 |
| Predicting Effective Truvada® PrEP Dosing Strategies With a Novel PK-PD Model Incorporating Tissue Active Metabolites and Endogenous Nucleotides (EN) ML Cottrell, KH Yang, HMA Prince, C Sykes, N White, S Malone, ... AIDS Research and Human Retroviruses 30 (S1), A60-A60, 2014 | 30 | 2014 |
| Concentrations of TFV and TFVdp in female mucosal tissues after a single dose of TAF KL Garrett, ML Cottrell, HM Prince, C Sykes, A Schauer, A Peery, ... Conference on Retroviruses and Opportunistic Infections, 22-25, 2016 | 28 | 2016 |
| Antiretroviral therapy concentrations differ in gut vs. lymph node tissues and are associated with HIV viral transcription by a novel RT-ddPCR assay SA Lee, S Telwatte, H Hatano, ADM Kashuba, ML Cottrell, R Hoh, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 83 (5), 530-537, 2020 | 25 | 2020 |
| Contemporary drug–drug interactions in HIV treatment AS Devanathan, DJC Anderson, ML Cottrell, EM Burgunder, ... Clinical Pharmacology & Therapeutics 105 (6), 1362-1377, 2019 | 25 | 2019 |
| Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones L Li, GJ Gatto, RM Brand, SA Krovi, ML Cottrell, C Norton, ... Journal of Controlled Release 340, 188-199, 2021 | 24 | 2021 |
| Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs P Maturavongsadit, R Shrivastava, C Sykes, ML Cottrell, SA Montgomery, ... International journal of pharmaceutics 605, 120844, 2021 | 21 | 2021 |
| A pharmacokinetic/pharmacodynamic model to predict effective HIV prophylaxis dosing strategies for people who inject drugs KL Garrett, J Chen, BM Maas, ML Cottrell, HA Prince, C Sykes, ... Journal of Pharmacology and Experimental Therapeutics 367 (2), 245-251, 2018 | 20 | 2018 |
